---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263534"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:40:42.080838+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA

## Summary
- First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.
- Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.
- Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.
- Topline results from primary and secondary endpoints are anticipated in 2027.

## SEC filing metadata
- accession: 0001193125-25-263534
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/0001193125-25-263534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263534
- JSON: https://secwatch.observer/filing/0001193125-25-263534.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.